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Purpose: The aim of this study was to compare survival of patients with uterine 
sarcomas using the 1988 and 2008 International Federation of Gynecologists and 
Obstetricians (FIGO) staging systems to determine if revised 2008 staging accu-
rately predicts patient survival. Materials and Methods: A total of 83 patients 
with leiomyosarcoma and endometrial stromal sarcoma treated at Yonsei Universi-
ty Health System between March of 1989 and November of 2009 were reviewed. 
The prognostic validity of both FIGO staging systems, as well as other factors was 
analyzed. Results: Leiomyosarcoma and endometrial stromal sarcoma comprised 
47.0% and 53.0% of this study population, respectively. Using the new staging 
system, 43 (67.2%) of 64 eligible patients were reclassified. Among those 64 pa-
tients, 45 (70.3%) patients with limited uterine corpus involvement were divided 
into stage IA (n=14) and IB (n=31). Univariate analysis demonstrated a significant 
difference between stages I and II and the other stages in both staging systems 
(p<0.001) with respect to progression-free survival and overall survival (OS). Age, 
menopausal status, tumor size, and cell type were significantly associated with OS 
(p=0.011, p=0.031, p=0.044, p=0.009, respectively). In multivariate analysis, re-
vised FIGO stage greater than III was an independent poor prognostic factor with 
a hazard ratio of 9.06 [95% confidence interval (CI) 2.49-33.0, p=0.001]. Conclu-
sion: The 2008 FIGO staging system is more valid than the previous FIGO staging 
system for uterine sarcomas with respect to its ability to distinguish early-stage pa-
tients from advanced-stage patients.
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INTRODUCTION
 
Uterine sarcomas represent rare tumors that account for up to 7% of all uterine 
cancer.1 Since uterine sarcomas are rare and exhibit truly heterogeneous histopath-
ologic diversity, optimal treatment strategies have not been well established. Many 
reports suggest that the International Federation of Gynecologists and Obstetri-
cians (FIGO) stage is the most important prognostic factor and should primarily 
dictate treatment.2-8
Until 2008, uterine sarcomas were staged using the staging system designed for 
endometrial carcinomas in 1988. A revised FIGO classification and staging system 
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as means and standard deviations. Continuous variables were 
examined for a normal distribution (Kolmogorov-Smirnov 
test) before adopting parametric statistics. Generally, for all 
analyses p<0.05 was considered significant. 
RESULTS
 
LMS and ESS comprised 47.0% (39/83) and 53.0% (44/83) 
of the study population, respectively. The median follow-up 
was 57 months. Table 1 depicts the patient characteristics. 
Tumor size was significantly larger in patients with LMS, 
compared to cases with ESS. 
Sixty-four of the 83 patients were classified according to 
the FIGO staging system. Table 2 shows the comparison of 
the distribution of patients using the 1988 and 2008 FIGO 
staging systems. With the 2008 FIGO staging system, the 
largest numbers of patients (70.3%) were classified as stage 
I. The percentage of patients classified as stage II markedly 
increased with the 2008 FIGO staging system (from 0% to 
12.5%). Based on the 2008 FIGO system, downstaging oc-
curred in 42 patients (65.6%), and upstaging occurred in 
one patient (1.6%).
The 5-year estimated survival rates for patients with 1988 
FIGO stage IA, IB, and IC disease were 100%, 95%, and 
82%, respectively. When these patients were reclassified 
according to the 2008 FIGO staging system, the 5-year sur-
vival rates for stages IA and IB were 100% and 83.0%, re-
spectively (Fig. 1). Patients with 1988 FIGO stage IIIA dis-
ease had 5-year estimated survival outcomes similar to 
those of patients with 2008 FIGO stage IIA disease (63.0% 
and 60.0%, respectively).
Univariate analysis demonstrated significant differences 
between stages I, II, and other stages in both staging sys-
tems (p<0.001) with respect to PFS and OS (Fig. 2). Myo-
metrial invasion was not associated with survival. Howev-
er, age, menopausal status, tumor size, and cell type were 
significantly correlated with OS (p=0.011, p=0.031, p= 
0.044, p=0.009, respectively) (Table 3, Fig. 3). In multivari-
ate analysis, ESS cell type and 1988 FIGO stage >III were 
independent prognostic factors with a hazard ratio (HR) of 
0.22 [95% confidence interval (CI) 0.05-0.90, p=0.035] and 
6.47 (95% CI 2.03-20.60, p=0.002) respectively. However, 
there was no difference in survival between LMS and ESS 
in the multivariate model after adjusting for the 2008 FIGO 
staging system (HR 0.36, 95% CI 0.08-1.58, p=0.174) (Ta-
ble 4).
was introduced in 2008 for uterine sarcomas in order to re-
flect the differences in the biologic behavior.9,10 Tumor size 
was introduced as a staging variable in the revised FIGO 
staging system for uterine leiomyosarcoma and endometrial 
stromal sarcoma. In this new system, stage I disease is di-
vided into IA or IB according to the tumor size. Adnexal in-
volvement is now included within stage II. Thus it is pru-
dent to evaluate the FIGO staging system for its ability to 
predict prognosis and examine the relevance of changes 
made periodically to the staging system in an evidence 
based manner.
The objective of this study was to compare survival for 
patients with uterine leiomyosarcoma and endometrial stro-
mal sarcoma using the 1988 and 2008 the FIGO staging 
systems to determine if revised 2008 staging accurately 
predicts patient survival.
MATERIALS AND METHODS
　　　
A total of 83 patients with leiomyosarcoma (LMS) and en-
dometrial stromal sarcoma (ESS) were treated at Yonsei 
University Health System between March of 1989 and 
November of 2008. Nineteen patients were excluded due 
to incomplete surgery and difficulty in classification. A fi-
nal total of 64 patients were included in the study. Demo-
graphic data obtained from the medical record included 
age, parity, body mass index, menopausal status, initial 
symptoms, cell type, mode of surgery, tumor size, lymph 
node status, presence of myometrial invasion, and treat-
ment modality.
Progression-free survival (PFS) was measured from the 
date of diagnosis to the date of the first recurrence or pro-
gression of disease, or in the absence of recurrence, to the 
date of the last follow-up or death. Overall survival (OS) was 
calculated from the date of diagnosis to the date of death or 
last follow-up. Patients were staged according to both the 
1988 and 2008 FIGO staging systems. Survival analysis was 
performed using the Kaplan-Meier method with the log-
rank test for univariate analysis. Subsequently, multivariate 
analysis with Cox proportional hazards regression was per-
formed to determine which markers predicted PFS and OS 
after adjusting for the effects of known prognostic factors 
(FIGO stage, age, cell type, and tumor size). Data was ana-
lyzed using parametric and nonparametric statistics, SPSS 
19.0 (SPSS Inc., Chicago, IL, USA). Descriptive statistics 
were used for patient characteristic data, and are summarized 
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ing the stage I classification was proposed because the prog-
nosis of patients with stage IA, IB, and IC disease was not 
statistically significant. In our study, the 5-year survival rate 
of patients with the 1988 stage IC was similar to the 5-year 
survival rate of patients with the 2008 stage IB (82% vs. 
83%). It was also noteworthy that the 1988 FIGO stage IIIA 
disease and 2008 FIGO stage IIA had similar survival (63% 
DISCUSSION
The new FIGO staging systems for LMS and ESS were de-
veloped in 2008. Early stage cancer (i.e., stage I) was sub-
classified into stages IA and IB for the first time by tumor 
size and not by the depth of myometrial invasion. Modify-
Table 1. Patient Characteristics
Total, n=83 (%) LMS, n=39 (%) ESS, n=44 (%) p value
Age 45.7±11.1 47.2±11.6 44.2±10.8    0.227*
Parity   0.835‡ 
    Null 13 (16)   6 (15)   7 (16)
    Para 70 (84) 33 (85) 37 (84)
Menopausal status   0.074‡ 
    Yes 27 (33) 17 (44) 10 (23)
    No 56 (67) 22 (56) 34 (77)
BMI 22.7±3.2 22.9±3.2 22.5±3.3    0.600*
Mode of cancer verification <0.001§ 
    Hysterectomy 48 (58) 25 (64) 23 (52)
    Myomectomy 4 (5)   4 (10) 0 (0)
    Endometrial biopsy 19 (23) 2 (5) 17 (39)
    Suspicious lesion 11 (13)   8 (21) 3 (7)
Symptom   0.141‡ 
    Bleeding 29 (35) 11 (28) 18 (41)
    Mass 43 (52) 20 (51) 23 (52)
    Pain 11 (13)   8 (21) 3 (7)
Mode of surgery   0.147‡ 
    TAH+BSO 37 (45) 22 (56) 15 (34)
    Staging operation|| 46 (55) 17 (43) 29 (66)
Myometrial invasion   0.187§ 
    No 1 (1) 0 (0) 1 (2)
    Less than half 24 (29)   9 (23) 15 (34)
    More than half 27 (33) 16 (41) 11 (25)
    Unknown 31 (37) 14 (36) 17 (39)
    Tumor size 8.75 (1-25)        10 (2.6-25)      6 (1-20) <0.001† 
LN status   0.413‡ 
    Yes 2 (2) 1 (3) 1 (2)
    No 27 (33)   9 (23) 18 (41)
    Unknown 54 (65) 29 (74) 25 (57)
Adjuvant therapy   0.009‡ 
    CT 19 (23) 13 (33)   6 (14)
    RT 10 (12)   6 (15) 4 (9)
    CCRT 7 (8) 2 (5)   5 (11)
    Unknown   9 (11)   7 (18) 2 (5)
LMS, leiomyosarcoma; ESS, endometrial stromal sarcoma; BMI, body mass index; TAH, total abdominal hysterectomy; BSO, bilateral salpingo-oophorec-
tomy; LN, lymph node; CT, chemotherapy; RT, radiotherapy; CCRT, concurrent chemoradiation.
*t-test.
† Mann-Whitney U test.
‡ Chi-square test.
§ Fisher’s exact test.
||Staging operation includes TAH, BSO, pelvic and paraaortic lymph node assessment. 
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ESS has traditionally been divided into LESS and high-
grade ESS (HESS) according to morphology, mitotic activ-
ity, cellularity, and the presence of necrosis. HESS is char-
acterized by an aggressive clinical course, thus, it has been 
suggested that HESS should be reclassified as an undiffer-
entiated or poorly-differentiated endometrial sarcoma and 
not remain part of the ESS category.15,16 However, in this 
study, histologic subtype did not impact survival. Because 
of the rarity of ESS, only 4 cases of HESS were included in 
our study.
In a study of 208 LMS patients, tumor size was a major 
and 60.0%, respectively).
Various clinicopathologic studies on uterine sarcomas 
have found that stage is an important independent predictor 
of OS.2-6 However, the impact of other prognostic factors 
including age, tumor size, FIGO stage, depth of myometrial 
invasion, tumor grade, mitotic activity, and DNA ploidy on 
survival is unclear or controversial, especially for ESS.11-13 
In the largest study of low endometrial stromal sarcoma 
(LESS), tumor size correlated poorly with outcome, but, 
mitotic activity and cytologic atypia were not predictive of 
tumor recurrence in stage I tumors.14 
Table 2. Reclassification Using the Revised 2008 FIGO Stage
1988 FIGO stage 2008 FIGO stage
LMS (%) ESS (%) LMS (%) ESS (%)
Stage I         21 (54)        24 (56)         21 (54)        24 (56)
    IA   0   1   2 12
    IB 10 12 19 12
    IC 11 11 - -
Stage II   0   0           4 (10)           4 (10)
    IIA   0   0   2   3
    IIB   0   0   2   1
Stage III           6 (15)           5 (12)           6 (15)         1 (2)
    IIIA   5   4   2   0
    IIIB   0   0   3   1
    IIIC   1   1   1   0
Stage IV           5 (12)         3 (7)         1 (2)         3 (7)
    IVA   0   0   0   1
    IVB   5   3   1   2
Unclassified           8 (19)         11 (25)           8 (19)         11 (25)
FIGO, International Federation of Gynecologists and Obstetricians; LMS, leiomyosarcoma; ESS, endometrial stromal sarcoma.  
Fig. 1. Survival curves for patients with stage I disease according to the 1988 FIGO staging system (A) and 2008 FIGO staging system (B).
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Fig. 2. Survival curves by stage.
Fig. 3. Survival curves by the tumor size and depth of myometrial invasion.
Table 3. Univariate Analysis of Prognostic Factors
Variable PFS, p value OS, p value
Age (≥50)   0.017   0.011
Menopausal status   0.030   0.031
Tumor size (≥5 cm)   0.004   0.044
Myometrial invasion (≥1/2)   0.119   0.117
LMS/ESS   0.025   0.009
LESS/HESS   0.035   0.406
Stage I, II vs. III, IV (2008) <0.001 <0.001
Stage I, II vs. III, IV (1988) <0.001 <0.001
PFS, progression-free survival; OS, overall survival; LMS, leiomyosarcoma; ESS, endometrial stromal sarcoma; LESS, low-grade endometrial stromal sar-
coma; HESS, high-grade endometrial stromal sarcoma. 
Overall survival (months)
Overall survival (months)
Overall survival (months)
Overall survival (months)
0.0
0.0
0.0
0.0
0.2
0.2
0.2
0.2
0.4
0.4
0.4
0.4
0.6
0.6
0.6
0.6
0.8
0.8
0.8
0.8
1.0
1.0
1.0
1.0
Su
rv
iva
l p
ro
ba
bi
lit
y
Su
rv
iva
l p
ro
ba
bi
lit
y
Su
rv
iva
l p
ro
ba
bi
lit
y
Su
rv
iva
l p
ro
ba
bi
lit
y
0
0
0
0
50
50
50
50
100
100
100
100
150
150
150
150
200
200
200
200
250
250
250
250
300
300
300
300
1988 I
<5 cm
≥5 cm
II
<1/2
III
≥1/2
IV
1988 III
1988 IV
I
No
p<0.001
p=0.044
p<0.001
p=0.283
Ga Won Yim, et al.
Yonsei Med J   http://www.eymj.org   Volume 55   Number 3   May 2014568
mated survival rates of patients with 1988 stage IIIA and 
2008 stage IIA were 63.0% and 60.0%, respectively. There-
fore, revisions appear appropriate based on similar survival 
outcomes in patients with adnexal invasion. The revised stag-
ing system discriminates among the early stage patients more 
than the advanced stage patients. The revised FIGO stage 
was an independent parameter in multivariate analysis. 
However, the number of patients with advanced stage dis-
ease was too small to show the comparison survival out-
come by staging system.
There are some limitations to our study. A relatively small 
number of patients were included in the analysis. Addition-
ally, this retrospective chart review may have unmeasured 
confounders. However, this is the first report to show the 
discriminating impact of survival outcomes between the 
1988 and 2008 staging systems for uterine sarcomas.
Standard staging procedures for uterine sarcoma have not 
yet been determined. The utility of procedures for peritone-
al staging, including peritoneal washing cytology, peritone-
al biopsy, and omentectomy in the absence of gross extra-
uterine disease, needs further evaluation to verify the impact 
on survival. More definitive conclusions regarding the re-
vised FIGO staging system for uterine sarcomas may be val-
idated with larger populations involving multiple centers. 
In conclusion, the 2008 FIGO staging system is more 
valid than the previous system for LMS and ESS with re-
spect to its ability to distinguish early stage patients from pa-
tients with advanced stage disease. However, no significant 
prognostic validity was observed between stage III and IV 
due to the rare occurrence of patients in those stages.
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